Our Pipeline
Proprietary pipeline
We develop innovative therapeutics aimed at improving the lives of cancer patients. We have built a robust pipeline leveraging our small molecule expertise in targeted protein degradation, immuno-oncology, precision oncology, and epigenetics
Development stage
Program
MOA
Rights
Indications
Discovery
Pre-clinical
IND-enabling
Clinical Phase I
Clinical Phase II
Clinical Phase III
CA-170
VISTA antagonist
CA-170, VISTA Inhibitor
Stage – Clinical Phase 3
CA-170 is an oral, small molecule VISTA inhibitor. In contrast to antibodies, CA-170 offers the advantages of ease of dosing, the ability to manage immune-related adverse events (irAEs), and lower COGS.
Global
NSCLC, bladder & kidney cancers
AUR103
CD47 antagonist
AUR103, CD47 antagonist
Stage – Clinical Phase 1
AUR103 is a highly differentiated oral small molecule inhibitor of CD47. In pre-clinical studies, AUR103 does not show hemotoxicity. This is in contrast to anti-CD47 antibodies, where significant dose-limiting toxicities of anemia, thrombocytopenia, and leukopenia have been observed.
Global
Leukaemia, lymphoma and multiple solid tumors
AUR104
FABP5 inhibitor
AUR104, First-in-class inhibitor of Fatty-Acid Binding Protein 5 (FABP5)
Stage – Clinical Phase 1
It is a first in class novel anticancer compound that inhibits FABP5 and affects the BCR pathway. It is in clinical evaluation as a monotherapy in patients with NHL and CLL who have progressed on prior standard therapies.
Global
Lymphoma and solid tumors
AUR105
PRMT5 inhibitor
AUR105, PRMT5 inhibitor
Stage – Clinical Phase 1
A substrate competitive inhibitor of PRMT5, with a high tumor/plasma ratio in xenograft studies. AUR105 has demonstrated significant efficacy in multiple pre-clinical cancer models.
Global
Leukaemia, lymphoma and multiple solid tumors
AUR106
TIGIT antagonist
AUR106, TIGIT antagonist
Stage – Clinical Phase 1
An oral, small molecule inhibitor of TIGIT and PDL1, developed from Aurigene’s small molecule IO platform. In contrast to antibodies, AUR106 offers the advantages of ease of combination dosing, the ability to manage immune-related adverse events (irAEs), and lower COGs.
Global
Multiple cancers
AUR107
CBP/p300 inhibitor
AUR107, CBP/p300 inhibitor
Stage – Clinical Phase 1
AUR107 is an oral, dual inhibitor of CBP and p300 with excellent selectivity against other bromodomain containing proteins. The molecule has demonstrated excellent efficacy in pre-clinical models with good therapeutic margins.
Global
NSCLC, lymphomas, leukemias, bladder cancers and prostate cancers
AUR108
DHODH inhibitor
AUR108, DHODH inhibitor
Stage – Clinical Phase 1
AUR108 (formerly known as AG-636) is an oral, potent DHODH inhibitor with high selectivity against a panel of dehydrogenases. It has broad activity in pre-clinical models of lymphoma and leukemia, with a potential for combination with standard of care.
Global
Leukaemia and lymphoma
AUR109
DDR1/SIK2 inhibitor
AUR109, DDR1/SIK2 inhibitor
Stage – Clinical Phase 2A
AUR109 (formerly known as ODM-203) is an oral, spectrum selective kinase inhibitor targeting DDR1 and SIK2 along with clinically validated targets FGFRs and VEGFRs. It is currently being evaluated in FGFR mutant bladder cancer. The unique selectivity profile allows potential expansion of indications.
Global
Cancers of bladder, lung, breast, ovary, kidney, liver & lung fibrosis
AUR101
RORgt inverse agonist
AUR101, RORgt inverse agonist
Stage – Clinical Phase 2B
AUR101 is an oral, small molecule RORgt inverse agonist. It is the most advanced clinical asset in this class, being developed for the treatment of moderate to severe psoriasis.
Global
Psoriasis, Psoriatic arthritis, Ankylosing spondylitis
AUR112
MALT1 Inhibitor
Global
Lymphoma, R/R NHL, CLL
Program
MOA
Rights
Indications
Discovery
Pre-clinical
IND-enabling
Clinical Phase I
Clinical Phase II
Clinical Phase III
AUR110#
Selective SMARCA2
Global
SMARCA- 4 mutant cancers
AUR114
Pan-KRAS
Global
Cancers of the lung, pancreas and colon
Program
MOA
Rights
Indications
Discovery
Pre-clinical
IND-enabling
Clinical Phase I
Clinical Phase II
Clinical Phase III
CDK 12/13 Inhibitor 1
Global
Breast, Ovarian and Prostate cancers
CCR4 antagonist
Global
Atopic dermatitis, Asthma and oncology
SMARCA2/4 dual degrader
Global
Prostate cancer, leukemia, lymphoma and myeloma
PDL1/A2AR dual inhibitor
Global
Multiple cancers
p300 selective degrader
Global
CBP mutant cancers, breast and prostate cancers
CBP selective degrader
Global
p300 mutant cancers
SMARCA2 oral degrader
Global
SMARCA- 4 mutant cancers
KIF18A inhibitor
Global
Ovarian, breast and other with high chromosomal instability
SIRPα/β*
Global
Multiple solid tumours
* Antibody programs # IND approved
Clinical Candidates from Partnered Programs
Here are the key compounds discovered at Aurigene in clinical development.
Partner
Target & Compound
Pre-clinical
Clinical Phase I
Clinical Phase II
Clinical Phase III
Novartis
(licensed to Laekna)
CYP17, CFG920
Astellas
PPARδ modulator, ASP0367 #
PPARδ modulator, ASP1128 #
BACH1, ASP8731 #
Asana Biosciences
SYK/JAK, ASN002
BRAK/PI3K, ASN003
Eisai
ESR1, H3B-6545
Curis
IRAK4, CA4948
- Licensed/co-development programs
# Discontinued